DE69739828D1 - Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums - Google Patents

Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums

Info

Publication number
DE69739828D1
DE69739828D1 DE69739828T DE69739828T DE69739828D1 DE 69739828 D1 DE69739828 D1 DE 69739828D1 DE 69739828 T DE69739828 T DE 69739828T DE 69739828 T DE69739828 T DE 69739828T DE 69739828 D1 DE69739828 D1 DE 69739828D1
Authority
DE
Germany
Prior art keywords
agents
ppargamma
methods
pharmaceutical compositions
tumor growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739828T
Other languages
German (de)
English (en)
Inventor
Bruce M Spiegelman
Soner Altiok
Elisabetta Mueller
Pasha Serraf
Peter Tontonoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/923,346 external-priority patent/US6552055B2/en
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE69739828D1 publication Critical patent/DE69739828D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69739828T 1996-12-11 1997-12-11 Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums Expired - Lifetime DE69739828D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76655396A 1996-12-11 1996-12-11
US08/923,346 US6552055B2 (en) 1996-12-11 1997-09-04 Methods and pharmaceutical compositions for inhibiting tumor cell growth

Publications (1)

Publication Number Publication Date
DE69739828D1 true DE69739828D1 (de) 2010-05-12

Family

ID=27117766

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69739828T Expired - Lifetime DE69739828D1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums
DE69726182T Expired - Lifetime DE69726182T2 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69726182T Expired - Lifetime DE69726182T2 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor

Country Status (8)

Country Link
US (1) US7635708B2 (enExample)
EP (2) EP1410799B1 (enExample)
JP (2) JP4549443B2 (enExample)
AT (2) ATE253903T1 (enExample)
AU (1) AU5601898A (enExample)
CA (1) CA2274756C (enExample)
DE (2) DE69739828D1 (enExample)
WO (1) WO1998025598A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029120A1 (en) * 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1143953A3 (en) * 1998-11-20 2002-02-06 Genentech, Inc. Method of inhibiting angiogenesis
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
WO2001052789A2 (en) 2000-01-20 2001-07-26 The Brigham And Women's Hospital, Inc. PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
AU2001278738A1 (en) * 2000-08-16 2002-02-25 Sankyo Company Limited Medicinal compositions for preventing and treating cancer
US20020054869A1 (en) 2000-09-01 2002-05-09 Han-Mo Koo Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
WO2002080913A1 (en) * 2001-04-06 2002-10-17 F. Hoffmann-La Roche Ag Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US20040197834A1 (en) * 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
WO2003053440A1 (en) * 2001-12-11 2003-07-03 Sankyo Company, Limited Medicinal composition
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
AU2003220855A1 (en) * 2002-04-01 2003-10-13 Sankyo Company, Limited Medicinal antitumor composition
AU2003246187A1 (en) * 2002-06-25 2004-01-06 Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING DIURETIC AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) Gamma ACTIAVTOR
JP2004083574A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2006232754A (ja) * 2005-02-25 2006-09-07 Gi Biopolis:Kk 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
EP1858512A4 (en) * 2005-03-14 2009-08-05 Immunomedics Inc METHOD FOR CREATING TREATMENT WITH PPAR GAMMA ANTAGONISTS
EP1865954A4 (en) 2005-03-21 2010-12-15 Metabolex Inc METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER
CA2623638A1 (en) 2005-09-30 2007-04-12 Vitae Pharmaceuticals, Inc. Treatment of cancer with specific rxr agonists
JP5186217B2 (ja) 2005-11-28 2013-04-17 千寿製薬株式会社 Ｐｐａｒアゴニスト含有医薬
WO2008143254A1 (ja) 2007-05-21 2008-11-27 Senju Pharmaceutical Co., Ltd. ＰＰＡＲδアゴニスト含有医薬
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
BR112013033674A2 (pt) 2011-06-29 2018-07-17 Penn State Res Found composições, métodos e kits para tratamento da leucemia
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
JP5987175B2 (ja) * 2012-07-02 2016-09-07 学校法人福岡大学 乳癌，胃癌及び卵巣癌等に対する制癌剤
DK2914250T3 (en) 2012-11-05 2018-06-18 Commissariat Energie Atomique COMBINATION OF ANTICANCER SUCH AS A TYROSINKINASE INHIBITOR AND A STAT5 ANTAGONIST, PRIOR TO A THIAZOLIDE INDION FOR ELIMINATING HEMATOLOGICAL CANCER STAM CELLS IN VIVO AND FOR THE PREVENTION OF RECIDIVISM OF RECIDIVES
EP3191095A2 (en) * 2014-09-08 2017-07-19 Dana Farber Cancer Institute, Inc. Methods of treating cancer comprising administering a ppar-gamma agonist
KR102489706B1 (ko) 2015-10-31 2023-01-17 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
US20190365681A1 (en) * 2015-10-31 2019-12-05 Io Therapeutics, Inc. Treatment of cancer with combinations of rxr agonists and thyroid hormones
WO2017151836A1 (en) * 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
MX386643B (es) 2016-03-10 2025-03-19 Io Therapeutics Inc Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas.
EP3426303B1 (en) 2016-03-10 2022-06-15 IO Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CA3191858A1 (en) * 2020-09-08 2022-03-17 National University Corporation Ehime University Fluorescent dye and method for detecting tumor cells
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DK0637297T3 (da) * 1992-04-22 2000-09-18 Ligand Pharm Inc Forbindelser, der har selektivitet til retinoid-X-receptorer
US5552271A (en) * 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
WO1994022857A1 (fr) * 1993-04-07 1994-10-13 Taiho Pharmaceutical Co., Ltd. Derive de thiazolidine et composition pharmaceutique contenant ce derive
JPH09505731A (ja) 1993-10-22 1997-06-10 リガンド・ファーマシューティカルズ・インコーポレーテッド ヒトペルオキシソーム増殖因子活性化レセプター
WO1995018533A1 (en) 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
US5514821A (en) * 1994-05-27 1996-05-07 Ligand Pharmaceuticals Incorporated Ring-labeled retinoids and intermediates, and methods for their synthesis and use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO1996001430A2 (en) 1994-07-01 1996-01-18 Ligand Pharmaceuticals, Incorporated Screening for nuc inhibitors
EP0769052A2 (en) 1994-07-01 1997-04-23 The Salk Institute For Biological Studies Mammalian peroxisome proliferator-activated receptors and uses thereof
CZ288526B6 (cs) 1994-08-10 2001-07-11 F. Hoffmann-La Roche Ag Deriváty tetrahydronaftalenu nebo indanu, farmaceutické přípravky na jejich bázi a meziprodukty pro přípravu těchto derivátů
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
EP0824583A1 (en) * 1995-05-04 1998-02-25 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
PT859608E (pt) * 1995-09-18 2004-06-30 Ligand Pharm Inc Tratamento de niddm com agonistas de rxr
CA2235036A1 (en) * 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
EP1410799A1 (en) 2004-04-21
CA2274756C (en) 2007-03-13
ATE253903T1 (de) 2003-11-15
WO1998025598A3 (en) 1998-07-30
EP1410799B1 (en) 2010-03-31
DE69726182T2 (de) 2004-08-12
DE69726182D1 (de) 2003-12-18
AU5601898A (en) 1998-07-03
ATE462433T1 (de) 2010-04-15
WO1998025598A2 (en) 1998-06-18
US7635708B2 (en) 2009-12-22
JP2009063566A (ja) 2009-03-26
US20030144330A1 (en) 2003-07-31
JP2001510462A (ja) 2001-07-31
CA2274756A1 (en) 1998-06-18
EP0948324A2 (en) 1999-10-13
EP0948324B1 (en) 2003-11-12
JP4550133B2 (ja) 2010-09-22
JP4549443B2 (ja) 2010-09-22

Similar Documents

Publication Publication Date Title
DE69739828D1 (de) Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69937646D1 (de) vORRICHTUNG ZUR BEHANDLUNG DER HARNINKONTINENZ
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
DE69916035D1 (de) Vorrichtung zur behandlung von halbleiterscheiben
MXPA02005196A (es) Inhibidores de deacetilasa de histona.
DK0986382T3 (da) RAF-kinasehæmmere
ATE294595T1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
NO985652L (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
ATE418999T1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
AR024138A1 (es) Inhibidores de la proliferacion celular
DE3779930D1 (de) Zusammensetzungen zur oberflaechenbehandlung, polymere dafuer und verfahren zur oberflaechenbehandlung.
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
NO20010956L (no) Modulering av hukommelseseffektor T-celler samt midler for dette
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
IS3037A7 (is) Útbúnaður til að nema burtu yfirborð af vöðvavef dýra, einkum fiskflaka
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
DE69911582D1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
DE69932342D1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition